NextCure, Inc. is currently facing a critical situation regarding its listing on the Nasdaq Global Select Market. The company received a notice from Nasdaq indicating that it does not meet the minimum stockholders' equity requirement. This development is significant as it could lead to delisting if not addressed promptly.

On November 16, 2026, NextCure was informed that its stockholders' equity of $5.5 million fell short of the required minimum of $10 million. Additionally, the company did not meet alternative compliance standards related to market value and total assets. The notice has raised concerns about NextCure's financial health and its ability to remain listed on a major exchange.

NextCure, Inc., categorized under the SIC code 2834 for Pharmaceutical Preparations, operates in a highly competitive industry. The company is publicly traded on the Nasdaq under the ticker NXTC. Its recent filings indicate that it is a smaller reporting company, which may impact its compliance strategies.

The SEC filing (accession number 0001104659-26-130409) details the company's current predicament. In response to the notice, NextCure has 45 days to submit a plan to regain compliance with Nasdaq's requirements. This plan must be submitted by January 4, 2027. However, the company is optimistic that its ongoing merger with Avere Therapeutics will close before this deadline, potentially resolving its compliance issues.

The proposed merger with Avere Therapeutics is expected to be finalized in mid-December 2026, pending stockholder approval and other customary conditions. If successful, this merger could enhance NextCure's financial standing and help it meet the necessary equity requirements to remain listed on Nasdaq. The company believes that completing the merger would eliminate the need to submit a compliance plan.

As of now, NextCure's common stock continues to be listed and traded on the Nasdaq, but the company must adhere to other listing requirements to maintain its status. The notice from Nasdaq does not have an immediate effect on trading, yet the situation underscores the importance of compliance in the pharmaceutical sector.

NextCure's challenges reflect broader issues within the pharmaceutical preparations industry, where companies often face stringent regulatory and financial requirements. The outcome of NextCure's merger with Avere will be pivotal in determining its future viability in the market.

Looking ahead, NextCure is focused on completing the merger with Avere Therapeutics, which could stabilize its financial situation. If the merger does not close before the grace period ends, the company plans to submit a compliance plan to Nasdaq. The coming weeks will be critical for NextCure as it navigates these challenges.